ConductScience.org, home

Paper27445495

Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis.

De Santis S and 6 others. Onco Targets Ther, 2016. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis. Papers, record 27445495. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27445495

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis.
PubMed
Journal
Onco Targets Ther
PubMed
Year
2016
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
0.59
iCite
Revised in PubMed
2020-09-30
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1De Santis SStefano
2Borghesi CCristina
3Ricciardi SSerena
4Giovannoni DDaniele
5Fulvi AAlberto
6Migliorino MRMaria Rita
7Marcassa CClaudio

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111755892Incidence, prevalence, and management of opioid bowel dysfunction.Am J Surg2001https://conductscience.org/library/papers/11755892PubMed
221249653Laxatives or methylnaltrexone for the management of constipation in palliative care patients.Cochrane Database Syst Rev2011https://conductscience.org/library/papers/21249653PubMed
311068116Defining the clinically important difference in pain outcome measures.Pain2000https://conductscience.org/library/papers/11068116PubMed
421937568
A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.
Palliat Med2012https://conductscience.org/library/papers/21937568PubMed
523680581Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis.J Pain Symptom Manage2013https://conductscience.org/library/papers/23680581PubMed
626644526Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain.J Clin Oncol2016https://conductscience.org/library/papers/26644526PubMed
723748119Interventional management of neuropathic pain: NeuPSIG recommendations.Pain2013https://conductscience.org/library/papers/23748119PubMed
821401835Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.Int J Clin Pract2011https://conductscience.org/library/papers/21401835PubMed
922312101American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care.J Clin Oncol2012https://conductscience.org/library/papers/22312101PubMed
1021343919Opioid-induced constipation: challenges and therapeutic opportunities.Am J Gastroenterol2011https://conductscience.org/library/papers/21343919PubMed
1124249829Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study.Am J Hosp Palliat Care2014https://conductscience.org/library/papers/24249829PubMed
1222313329
Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis.
J Med Econ2012https://conductscience.org/library/papers/22313329PubMed
1323577077
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.
PLoS One2013https://conductscience.org/library/papers/23577077PubMed
1425575709Informed drug choices for neuropathic pain.Lancet Neurol2015https://conductscience.org/library/papers/25575709PubMed
1521576968Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study.Eur Neurol2011https://conductscience.org/library/papers/21576968PubMed
1620851519NeuPSIG guidelines on neuropathic pain assessment.Pain2011https://conductscience.org/library/papers/20851519PubMed
1721865137Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.Clin Transl Oncol2011https://conductscience.org/library/papers/21865137PubMed
1822300860Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.Lancet Oncol2012https://conductscience.org/library/papers/22300860PubMed
1919244085Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes.Ann Oncol2009https://conductscience.org/library/papers/19244085PubMed
2023215628Combined oral prolonged-release oxycodone and naloxone in chronic pain management.Expert Opin Investig Drugs2013https://conductscience.org/library/papers/23215628PubMed

See all 46 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
38793067Managing Severe Cancer Pain with Oxycodone/Naloxone Treatment: A Literature Review Update.J Pers Med2024https://conductscience.org/library/papers/38793067PubMed
37679047Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions.J Pharmacol Exp Ther2023https://conductscience.org/library/papers/37679047PubMed
35117656Neurological paraneoplastic syndrome caused by small cell lung cancer: a case report.Transl Cancer Res2020https://conductscience.org/library/papers/35117656PubMed
34441829Combination Therapy for Neuropathic Pain: A Review of Recent Evidence.J Clin Med2021https://conductscience.org/library/papers/34441829PubMed
33642876Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain.Cancer Manag Res2021https://conductscience.org/library/papers/33642876PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TENM110178PubTator's text mininghttps://conductscience.org/library/genes/10178

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27445495

GET https://conductscience.org/api/papers/v1/27445495/references?page=2